| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
SLPC is not a therapeutic drug and has no defined pharmacological target. As a membrane phospholipid, it is recognized by various lipid-binding proteins and enzymes including phospholipases, lipid transport proteins, and membrane-associated signaling molecules. In research, SLPC serves as a substrate for studying enzymatic lipid oxidation and phospholipid metabolism.
|
|---|---|
| ln Vitro |
In vitro, SLPC is used as a model to study volatile compounds from oxidized phosphatidylcholine molecular species. It undergoes lipid peroxidation, particularly at the polyunsaturated linoleoyl chain, generating hydroperoxides, aldehydes, and other oxidation products. SLPC can be incorporated into liposomes for membrane biophysics studies. No specific pharmacological activity or therapeutic potency is reported.
|
| ln Vivo |
SLPC has no in vivo pharmacological activity as a therapeutic agent. It is a component of biological membranes and lipoproteins. When administered exogenously, SLPC can be incorporated into cell membranes and lipoproteins, potentially influencing lipid metabolism and membrane fluidity. It is also a component of soy lecithin and other natural lipid mixtures used in nutritional supplements.
|
| Enzyme Assay |
For in vitro oxidation studies, SLPC is dissolved in an appropriate organic solvent (e.g., chloroform or methanol) at a concentration of 1-10 mg/mL. The solvent is evaporated under nitrogen to form a lipid film. The film is hydrated in buffer (e.g., PBS, pH 7.4) with sonication to form liposomes or multilamellar vesicles. Oxidation is initiated by adding free radical initiators (e.g., AAPH) or exposing to UV light. Volatile oxidation products are collected and analyzed by GC-MS.
|
| Cell Assay |
For in vitro cell culture studies, SLPC is typically incorporated into liposomes for delivery to cells. Liposomes are prepared by dissolving SLPC with or without other lipids in organic solvent, evaporating the solvent, hydrating the lipid film in cell culture medium or buffer, and extruding to form unilamellar vesicles of defined size (50-200 nm). Cells are incubated with SLPC-containing liposomes for 4-48 hours. Cellular uptake can be tracked using fluorescently labeled lipid analogs.
|
| Animal Protocol |
For in vivo studies, SLPC is typically administered to rodents via intravenous injection (as liposomes) or oral gavage (as part of lipid emulsions). A typical intravenous dose of liposomal SLPC is 10-50 mg/kg. Blood samples are collected at multiple time points (0, 15, 30, 60, 120 min). Plasma lipid levels are analyzed by LC-MS to assess lipid clearance and distribution. Tissues (liver, spleen, kidney) can be collected for biodistribution studies.
|
| ADME/Pharmacokinetics |
SLPC is not a drug and no PK parameters are established for it. As a dietary phospholipid, SLPC is absorbed in the small intestine after digestion by pancreatic phospholipase A2 to lysophosphatidylcholine and free fatty acids. These products are incorporated into chylomicrons, transported via the lymphatic system, and distributed to tissues. The terminal elimination half-life of plasma phospholipids is typically several hours in rodents.
|
| Toxicity/Toxicokinetics |
SLPC is a naturally occurring phospholipid that is generally recognized as safe (GRAS) as a component of foods and dietary supplements at typical consumption levels. No significant toxicity is reported. High doses administered intravenously as liposomes may cause transient inflammatory responses. SLPC is a component of soy lecithin, which has low acute toxicity. Standard laboratory handling precautions are sufficient.
|
| References | |
| Additional Infomation |
1-Octadecanyl-2-[(9Z,12Z)-octadecadienoyl]-sn-glycerol-3-phosphocholine is a phosphatidylcholine 36:2, wherein the acyl groups at positions 1 and 2 are designated as octadecylyl and (9Z,12Z)-octadecadienoyl, respectively. It is a mouse metabolite. Its function is associated with linoleic acid and octadecanoic acid. 1-Stearyl-2-linoleyl-sn-glycerol-3-phosphocholine has been reported in Streptomyces roseicoloratus, Drosophila melanogaster, and Vitis vinifera, with relevant data available.
SLPC is not a drug and has no regulatory approval for therapeutic use. It is a research-use biochemical widely employed as a model compound for studying lipid oxidation, liposome preparation, and phospholipid biochemistry. SLPC is also a component of soy lecithin, used as an emulsifier in food and pharmaceutical formulations, but the purified compound is intended for research only. No clinical trials have been conducted with purified SLPC. |
| Molecular Formula |
C44H84NO8P
|
|---|---|
| Molecular Weight |
786.11
|
| Exact Mass |
785.593
|
| CAS # |
27098-24-4
|
| PubChem CID |
6441487
|
| Appearance |
White to off-white solid powder
|
| LogP |
12.794
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
42
|
| Heavy Atom Count |
54
|
| Complexity |
972
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC
|
| InChi Key |
FORFDCPQKJHEBF-VPUSDGANSA-N
|
| InChi Code |
InChI=1S/C44H84NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-43(46)50-40-42(41-52-54(48,49)51-39-38-45(3,4)5)53-44(47)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h15,17,21,23,42H,6-14,16,18-20,22,24-41H2,1-5H3/b17-15-,23-21-/t42-/m1/s1
|
| Chemical Name |
[(2R)-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-octadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2721 mL | 6.3604 mL | 12.7209 mL | |
| 5 mM | 0.2544 mL | 1.2721 mL | 2.5442 mL | |
| 10 mM | 0.1272 mL | 0.6360 mL | 1.2721 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
